X4 Pharmaceuticals receives Nasdaq deficiency notice for minimum bid price rule; 180 days to regain compliance

X4 Pharmaceuticals, Inc

On Aug 13, 2024, Nasdaq notified X4 that its common stock closing bid price was below $1.00 for 32 consecutive business days.
Company has until Feb 10, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.
If not compliant by Feb 10, X4 may be eligible for additional 180-day cure period if it meets other listing standards.
X4 says it will monitor bid price and consider options including a reverse stock split to cure deficiency.
There is no immediate delisting; stock continues trading under symbol XFOR on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.